Oppenheimer & Co. Inc. Purchases Shares of 10,382 Guardant Health, Inc. (NASDAQ:GH)

Oppenheimer & Co. Inc. purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 10,382 shares of the company's stock, valued at approximately $442,000.

Several other large investors have also made changes to their positions in GH. SBI Securities Co. Ltd. bought a new position in Guardant Health during the fourth quarter valued at about $43,000. Kimelman & Baird LLC bought a new stake in shares of Guardant Health during the 4th quarter worth about $58,000. NewEdge Advisors LLC increased its holdings in shares of Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after acquiring an additional 230 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Guardant Health in the 4th quarter valued at approximately $61,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Guardant Health in the 4th quarter valued at approximately $79,000. Institutional investors own 92.60% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on GH shares. UBS Group lifted their price objective on Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Piper Sandler reaffirmed an "overweight" rating and issued a $60.00 target price (up previously from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. TD Securities upped their price target on Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Scotiabank reissued an "outperform" rating on shares of Guardant Health in a research report on Monday, May 5th. Finally, Mizuho raised their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Friday, June 13th. Twenty-one analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $53.76.

Guardant Health Stock Up 0.1%

GH stock traded up $0.07 during midday trading on Thursday, reaching $50.25. The stock had a trading volume of 956,932 shares, compared to its average volume of 2,158,915. The firm has a market cap of $6.23 billion, a price-to-earnings ratio of -14.82 and a beta of 1.44. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $53.42. The business has a fifty day simple moving average of $45.41 and a two-hundred day simple moving average of $42.93.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. The business had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. The company's quarterly revenue was up 20.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.46) earnings per share. On average, equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Musa Tariq sold 3,213 shares of Guardant Health stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $49.47, for a total value of $158,947.11. Following the sale, the director owned 7,190 shares of the company's stock, valued at approximately $355,689.30. This trade represents a 30.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ian T. Clark sold 6,672 shares of Guardant Health stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $48.38, for a total transaction of $322,791.36. Following the completion of the sale, the director owned 9,851 shares in the company, valued at $476,591.38. This trade represents a 40.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 342,274 shares of company stock valued at $17,080,589. 6.10% of the stock is owned by company insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.